• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Cantor Fitzgerald initiated coverage on Acumen Pharmaceuticals with a new price target

    5/18/23 7:21:04 AM ET
    $ABOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ABOS alert in real time by email
    Cantor Fitzgerald initiated coverage of Acumen Pharmaceuticals with a rating of Overweight and set a new price target of $13.00
    Get the next $ABOS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ABOS

    DatePrice TargetRatingAnalyst
    6/17/2025$4.00Buy
    Citigroup
    7/26/2024$7.00Buy
    Citigroup
    12/12/2023$8.00Buy
    Deutsche Bank
    7/20/2023$9.00 → $14.00Buy
    BofA Securities
    5/18/2023$13.00Overweight
    Cantor Fitzgerald
    7/15/2022$15.00Buy
    BTIG Research
    6/30/2022$15.00Buy
    H.C. Wainwright
    1/21/2022$16.00 → $14.00Neutral → Buy
    B of A Securities
    More analyst ratings

    $ABOS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Citigroup initiated coverage on Acumen Pharmaceuticals with a new price target

      Citigroup initiated coverage of Acumen Pharmaceuticals with a rating of Buy and set a new price target of $4.00

      6/17/25 7:48:19 AM ET
      $ABOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Citigroup initiated coverage on Acumen Pharmaceuticals with a new price target

      Citigroup initiated coverage of Acumen Pharmaceuticals with a rating of Buy and set a new price target of $7.00

      7/26/24 7:19:00 AM ET
      $ABOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Deutsche Bank initiated coverage on Acumen Pharmaceuticals with a new price target

      Deutsche Bank initiated coverage of Acumen Pharmaceuticals with a rating of Buy and set a new price target of $8.00

      12/12/23 6:44:55 AM ET
      $ABOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ABOS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ra Capital Management, L.P. was granted 12,800 shares (SEC Form 4)

      4 - Acumen Pharmaceuticals, Inc. (0001576885) (Issuer)

      6/5/25 6:12:53 PM ET
      $ABOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Stoppel Laura was granted 12,800 shares (SEC Form 4)

      4 - Acumen Pharmaceuticals, Inc. (0001576885) (Issuer)

      6/5/25 6:05:34 PM ET
      $ABOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Stalfort John A Iii was granted 12,800 shares, increasing direct ownership by 7% to 185,124 units (SEC Form 4)

      4 - Acumen Pharmaceuticals, Inc. (0001576885) (Issuer)

      6/5/25 4:59:03 PM ET
      $ABOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care